Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...

Objective Macrophage activation syndrome (MAS), a subtype of secondary haemophagocytic lymphohistiocytosis (HLH), is a rare ...

Background Progesterone-induced blocking factor 1 (PIBF1), a protein produced by maternal lymphocytes upon exposure to progesterone during pregnancy, acts as an immunomodulator by suppressing several ...

Background SLE is a rare chronic autoimmune disease with polymorphic clinical manifestation and wide-ranging disease course with treatment tactics dependent on disease activity and organ involvement.

Understanding the factors contributing to poor treatment adherence, recognizing its consequences, and developing effective strategies to enhance adherence are key to improving patient outcomes in ...

Purpose TLR7 and TLR8 (TLR7/8) are members of the Toll-Like Receptor family that recognize single strand RNA. Activation of TLR7/8 within immune cells elevates pro-inflammatory cytokines and type ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids. 2 As ...

Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterized by persistent damage to multiple organs and tissues, including the skin, kidneys, cardiovascular system, and brain.

The British Isles Lupus Assessment Group (BILAG)-2004 index is a comprehensive disease activity instrument for systemic lupus erythematosus (SLE). 1 Its key advantages are the ability to capture rare ...

Objective Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently ...

Introduction SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in preparing patients with SLE and ...